ConductScience.org, home

Paper41111360

Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.

Barazzoni R and 10 others. Diabetes Obes Metab, 2026. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity. Papers, record 41111360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41111360

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.
PubMed
Journal
Diabetes Obes Metab
PubMed
Year
2026
PubMed
Publication types
Journal Article, Systematic Review, Network Meta-Analysis
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
3.03, provisional
iCite
Revised in PubMed
2026-07-18
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Barazzoni RRocco
2Monami MMatteohttps://orcid.org/0000-0001-9349-828X
3Buscemi SSilviohttps://orcid.org/0000-0003-0730-7649
4Busetto LLuca
5De Luca MMaurizio
6Navarra GGiuseppe
7Ragghianti BBenedetta
8Silverii GAGiovanni Antoniohttps://orcid.org/0000-0002-6695-3213
9Belluzzi AAmanda
10Mannucci EEdoardohttps://orcid.org/0000-0001-9759-9408
11Sbraccia PPaolo

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ObesityMajor topic
Bariatric SurgeryMajor topic
Anti-Obesity AgentsMajor topic
OverweightMajor topic
Humans
Randomized Controlled Trials as Topic
Practice Guidelines as Topic
Italy
Treatment Outcome
Weight Loss

Source PubMed

Download CSV of topics

References168

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126369473Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.Lancet2015https://conductscience.org/library/papers/26369473PubMed
231931977Adjustable gastric band surgery or medical management in patients with type 2 diabetes and obesity: three-year results of a randomized trial.Surg Obes Relat Dis2019https://conductscience.org/library/papers/31931977PubMed
39886891Treatment with orlistat reduces cardiovascular risk in obese patients.J Hypertens1998https://conductscience.org/library/papers/9886891PubMed
423180572Long-term results of a randomized clinical trial comparing Roux-en-Y gastric bypass with vertical banded gastroplasty.Br J Surg2013https://conductscience.org/library/papers/23180572PubMed
532976702Simultaneous robotic kidney transplantation and bariatric surgery for morbidly obese patients with end-stage renal failure.Am J Transplant2021https://conductscience.org/library/papers/32976702PubMed
636717470Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass for Treating Obesity in Patients > 65 Years Old: 3-Year Outcomes of a Randomized Trial.J Gastrointest Surg2023https://conductscience.org/library/papers/36717470PubMed
718376181Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study.Ann Surg2008https://conductscience.org/library/papers/18376181PubMed
826198306Long-term effects of laparoscopic sleeve gastrectomy versus roux-en-Y gastric bypass for the treatment of Chinese type 2 diabetes mellitus patients with body mass index 28-35 kg/m(2).BMC Surg2015https://conductscience.org/library/papers/26198306PubMed
934406598
Laparoscopic One Anastomosis Gastric Bypass Versus Laparoscopic Roux-en-Y Gastric Bypass Effects on Pre-existing Mild-to-Moderate Gastroesophageal Reflux Disease in Patients with Obesity: a Randomized Controlled Study.
Obes Surg2021https://conductscience.org/library/papers/34406598PubMed
1039612579
International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
Br J Surg2024https://conductscience.org/library/papers/39612579PubMed
1135131037
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Lancet Diabetes Endocrinol2022https://conductscience.org/library/papers/35131037PubMed
1237385275Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet2023https://conductscience.org/library/papers/37385275PubMed
1329043548Comparison of Short-Term Effectiveness and Postoperative Complications: Laparoscopic Gastric Plication vs Laparoscopic Sleeve Gastrectomy.Obes Surg2018https://conductscience.org/library/papers/29043548PubMed
1412087008Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.Diabetes Care2002https://conductscience.org/library/papers/12087008PubMed
1521339423Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial.Arch Surg2011https://conductscience.org/library/papers/21339423PubMed
1627353417GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.BMJ2016https://conductscience.org/library/papers/27353417PubMed
1729340679Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial.JAMA2018https://conductscience.org/library/papers/29340679PubMed
1839476339Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.N Engl J Med2024https://conductscience.org/library/papers/39476339PubMed
1917192328Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.Diabetes Care2007https://conductscience.org/library/papers/17192328PubMed
209702435Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.Diabetes Care1998https://conductscience.org/library/papers/9702435PubMed

See all 168 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42426361Efficacy and Safety of Anti-Obesity Medications for Weight Loss Maintenance in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Diabetes Obes Metab2026https://conductscience.org/library/papers/42426361PubMed
42387279Positioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses.Diabetes Obes Metab2026https://conductscience.org/library/papers/42387279PubMed
41954678Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives.Rev Endocr Metab Disord2026https://conductscience.org/library/papers/41954678PubMed
41533187Italian clinical practice GRADE-based guidelines on the diagnosis and treatment of overweight and obesity, endorsed by the Italian National Institute of Health.Eat Weight Disord2026https://conductscience.org/library/papers/41533187PubMed
41111360
Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.
Diabetes Obes Metab2026https://conductscience.org/library/papers/41111360PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41111360

GET https://conductscience.org/api/papers/v1/41111360/references?page=2